ClinicalTrials.gg
Not yet recruitingNCT04784039CARDDI-BELUpdated Feb 1, 2023

D-Dimer-based Indication for Transesophageal Echocardiography to Exclude Left Atrial Thrombus Before Cardioversion of Non-anticoagulated Atrial Fibrillation: A Multicenter Belgian Study

A Phase 4 interventional study of Transesophageal echocardiography and D-Dimer analysis in Atrial Fibrillation, sponsored by AZ Sint-Jan AV. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-01.

Sponsored by AZ Sint-Jan AV · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 9 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,368
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Atrial Fibrillation by AZ Sint-Jan AV — 3 open to participants now, 3 under way, none of them phase 3. Atrial Fibrillation · AZ Sint-Jan AV.

Planned enrollment
Largest of 11
1,368 · median 105
Started
2025
the only one that year
Phase 4
2 of 11
1 open now
Registered
9th of 11
by date

Among the 11 studies in Atrial Fibrillation by AZ Sint-Jan AV, this one has the largest planned enrollment, is the only one that started in 2025, is one of 2 in phase 4, and was the 9th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

3 of the 11 studies in Atrial Fibrillation by AZ Sint-Jan AV are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Atrial Fibrillation by AZ Sint-Jan AV, or all of them as a file.
02

Study summary

This trial aims at evaluating the number of thromboembolic events post cardioversion in patients receiving a direct current cardioversion with either prior transesophageal echocardiography or D-Dimer (DD) analysis.

Patients in need of a direct current cardioversion (DCCV), meeting the criteria for DCCV with prior transesophageal echocardiography (TEE), will be asked to participate in the CARDDI-BEL study.

Patients will be randomized on a 1:1 ratio to the TEE-group or DD-group. Patients in the TEE-group will receive TEE prior to cardioversion to exclude left atrial thrombus according to current guidelines [1]. In patients randomized to the DD-group, D-Dimer will be analyzed (cut-off defined by DDage). If the DDage > 10x patient's age, the analysis is suggestive for the presence of left atrial thrombus and the cardioversion will be performed with prior TEE. In case of negative DDage, no TEE will be used in the DD-group.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients older than 18 years
  • Patients with non-valvular atrial fibrillation scheduled for direct current cardioversion with prior TEE according to current guidelines
  • Patients willing to sign

Exclusion criteria

Exclusion Criteria:

  • Cardiac surgery within the previous 90 days.
  • Coronary percutaneous transluminal coronary angioplasty/stenting within the previous 90 days or myocardial infarction within the previous 60 days.
  • Significant congenital anomaly or other medical problem that in the opinion of the investigator would preclude enrollment
  • History of blood clotting disease or bleeding abnormalities.
  • Patients with valve implants
  • Women who are pregnant
  • Aortic aneurysm or dissection
  • Documented history of deep vein thrombosis within the last 6 months
  • Documented history of pulmonary embolism within the last 6 months
  • Unwilling or unable to provide .
  • Recent or stroke (90 days)
  • Instable angina
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,368 participants (estimated)

Study arms

  • Active comparator
    TEE-group

    Diagnostic Test: Transesophageal echocardiography

  • Active comparator
    DD-group

    Diagnostic Test: D-Dimer analysis

Interventions

  • Diagnostic testTransesophageal echocardiography

    Patients randomized to the TEE group will be scheduled for cardioversion with prior TEE

  • Diagnostic testD-Dimer analysis

    Patients randomized to the DD-group will be scheduled for cardioversion with prior D-Dimer analysis. In case of positive D-Dimer results, TEE will be performed prior to cardioversion

06

What researchers measure

Primary outcomes

  1. Incidence in thromboembolic events between both groups after 4 weeks follow-up

    The number of thromboembolic events (stroke, transient ischemic attack, ...) in the TEE and DD-group will be compared

    Time frame: up to 4 weeks after cardioversion

Secondary outcomes

  1. Correlation between D-Dimer-value (ng/L) and number of thrombi visible on TEE

    Time frame: Procedure (At time of cardioversion)

  2. Correlation of DD-value (ng/L) with flow velocity (m/s) in case of spontaneous contrast or suspicion of thrombus in left atrial appendage

    Time frame: Procedure (At time of cardioversion)

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2025; primary completion for Jan 2026, 12 months later.

Of 130 non-industry phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's planned 12 months is below that.

Counting every sponsor, half of 142 studies reached it within 48 months; a quarter within 27 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2021
First posted
Mar 5, 2021
StartEst.
Jan 1, 2025
Primary completionEst.
Jan 31, 2026
CompletionEst.
Jan 31, 2026
Last update
Feb 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04784039
Lead sponsor
AZ Sint-Jan AV
Responsible party
Sebastien Knecht (Principal Investigator, AZ Sint-Jan AV) — Principal investigator
First posted
Mar 5, 2021
Start date
Jan 1, 2025 (estimated)
Primary completion
Jan 31, 2026 (estimated)
Completion
Jan 31, 2026 (estimated)
Last update
Feb 1, 2023

Study contacts

Sébastien Knecht, MD, PhD
Contact
sebastien.knecht@azsintjan.be
003250452670
Sébastien Knecht, MD, PhD
principal investigator · AZ Sint-Jan AV

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion